The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

June 14, 2017 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Dr. Poddar also cites both generic hydroxychloroquine and colchicine, which sells for an average retail price of $162.65 for 30 capsules according to GoodRx.com, as concerns for his patients. “Despite the fact it’s generic, every patient’s insurance is different, and some of my patients may pay $200 for a month’s supply of colchicine. Sometimes, the drug companies give coupons to offset the cost, but some pharmacies won’t accept them. So patients may just go without their drug,” he says. “High uric acid levels can have cardiovascular manifestations, so there are long-term ramifications, not just one joint problem. You can’t just tell these patients to tough it out. It’s not just their joints. These are systemic diseases.”

You Might Also Like
  • High Cost of DMARDs Could Limit Medicare Patients’ Treatment Adherence
  • FDA’s Gottlieb Blames Industry ‘Kabuki Drug Pricing’ for High Costs
  • Rising Costs of Biologics in the U.S. Suggest Need for Negotiation Ability
Explore This Issue
June 2017
Also By This Author
  • Rheumatoid Arthritis Research Provides New Insights on Risk Factors, Identification Tools, Intervention

In his Kingsport, Tenn., rheumatology clinic, Christopher Morris, MD, also cites both colchicine and hydroxychloroquine as “outlandishly expensive, and most of our lupus patients are on generic Plaquenil,” he says. “If they only price a generic a few dollars less than the brand-name drug, there’s really no savings.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients may not understand how their drug coverage on Medicare supplemental plans work when they purchase these policies, says Dr. Morris. They may struggle to pay 20% of the cost of a year’s supply of a drug that costs $25,000. His practice must now devote one full-time staff person just to deal with prior authorizations and insurance company negotiations, he says.

“High-deductible plans may make patients reach a certain level of money spent before they cover the drugs. These patients may have to shell out several thousand dollars before their insurance kicks in,” says Dr. Morris.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Copays Add Up Quickly

Rheumatology health professionals also hear their patients express concerns about high insurance copays adding up quickly for physical therapy and other integrative treatments, says Christine Stamatos, DNP, ANP-C, director of the Fibromyalgia Wellness Center at Northwell Health in Babylon, N.Y.

“I have patients who have to pay $50 for each physical therapy session,” Dr. Stamatos says. “Some patients have insurance policies with a lower premium each month, but very high deductibles, so they may go without their therapy, and this is care that we know is so effective. So it’s frustrating and scary.”

In the rheumatology clinic at the University of Kentucky in Lexington, Associate Professor Elizabeth Salt, PhD, also observes patients delaying care due to higher out-of-pocket costs. “We see decreased healthcare utilization at the beginning of the year when deductibles have not been met, and an increase at the end of the year, trying to get in treatments before the year ends. I see delays in necessary procedures due to cost and patients unable to afford medications due to increased cost,” she says.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Practice Management Tagged With: Biologics, biosimilar, Compliance, cost, drug, generic, Healthcare, Medication, patient care, Rheumatic Disease, rheumatologist, TreatmentIssue: June 2017

You Might Also Like:
  • High Cost of DMARDs Could Limit Medicare Patients’ Treatment Adherence
  • FDA’s Gottlieb Blames Industry ‘Kabuki Drug Pricing’ for High Costs
  • Rising Costs of Biologics in the U.S. Suggest Need for Negotiation Ability
  • 8 Ways to Help Your Patients with Medication Costs

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.